Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Phase II trial (the ICON study) of iberdomide + cyclophosphamide/dex in RRMM (median 3 prior lines) shows median PFS of 17.6 months; most common grade 3-4 AEs were neutropenia (34 [56%] patients) and infections (21 [34%] patients).”
Title: Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
Authors: Charlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, Febe Smits, Alexandra J Croockewit, Mark-David Levin, Matthijs Westerman, Okke de Weerdt, Inger S Nijhof, Jurgen Wegman, Nina Smit, Christie P M Verkleij, Tuna Mutis, Kazem Nasserinejad, Ramses Kerstiens, Marjolein van der Klift, Laurens E Franssen, Maaike E M de Ruijter, Kaz Groen, Ellen van der Spek, Wilfried W H Roeloffzen, Sonja Zweegman, and Niels W C J van de Donk.
You can read the Full Article in The Lancet Haematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
